Is a cure for Parkinson's disease hiding inside us?
Santos. Jaime J; Pallarès. Irantzu I; Ventura. Salvador S
Key Findings
- LL‑37 is an innate immune peptide that can bind to α‑synuclein oligomers and fibrils
- Binding of LL‑37 reduces amyloid formation and neurotoxicity in cell models
- The idea is still theoretical – no human trials or dosing data yet
Practical Outcomes
- At this point you can’t take LL‑37 as a supplement, but the study hints that boosting your body’s own LL‑37 (for example with adequate vitamin D, which up‑regulates LL‑37) might be worth exploring. Keep an eye on future trials before trying any specific peptide protocol for Parkinson’s prevention or treatment.
Summary
The paper looks at whether our own natural peptide LL‑37 could help stop the protein clumps that damage brain cells in Parkinson's disease. Early lab work suggests LL‑37 can stick to those harmful clumps and might block them from forming, but the research is still at a very basic stage.
Abstract
α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?
Study Information
pubmed
2022
2022-02-19T00:00:00.000Z
10.1016/j.tibs.2022.02.001
13
15